Halozyme Therapeutics/$HALO
About Halozyme Therapeutics
Ticker
Industry
Employees
HALO Metrics
$6.9B
17.91
$3.02
1.27
-
Price and volume
Market cap
$6.9B
Beta
1.27
52-week high
$65.53
52-week low
$33.15
Average daily volume
1.4M
Financial strength
Current ratio
10.357
Quick ratio
8.749
Long term debt to equity
341.186
Total debt to equity
341.186
Interest coverage (TTM)
25.54%
Management effectiveness
Return on assets (TTM)
14.87%
Return on equity (TTM)
111.83%
Valuation
Price to earnings (TTM)
17.911
Price to revenue (TTM)
7.285
Price to book
15.21
Price to tangible book (TTM)
-17.95
Price to free cash flow (TTM)
17.575
Growth
Revenue change (TTM)
21.35%
Earnings per share change (TTM)
61.71%
3-year revenue growth (CAGR)
26.95%
3-year earnings per share growth (CAGR)
2.82%
What the Analysts think about HALO
Analyst Ratings
HALO Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
HALO Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
HALO News
FAQs
What’s the current market cap for Halozyme Therapeutics stock?
What is the P/E ratio for Halozyme Therapeutics stock?
Does Halozyme Therapeutics stock pay dividends?
No, Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Halozyme Therapeutics dividend payment date?
Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders.
What is the beta indicator for Halozyme Therapeutics?
Halozyme Therapeutics (HALO) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.